Literature DB >> 1623909

The postoperative pharmacokinetics of codeine.

K Persson1, M Hammarlund-Udenaes, O Mortimer, A Rane.   

Abstract

The metabolism and systemic availability of codeine have been studied in 12 patients after cholecystectomy. They were given 20 mg codeine as an IV bolus dose on the first day after surgery and 50 mg codeine as a single oral on the fourth day after surgery. Codeine had a medium to high extraction ratio and a total plasma clearance of 10.8 (4.3) ml.min-1.kg-1. The clearance varied four-fold between subjects. All the patients were extensive metabolizers with regard to the debrisoquine/sparteine polymorphism, as tested using dextromethorphan as the probe drug. Nevertheless, the formation of morphine from codeine was very small and plasma morphine concentrations were below the detection limit of 3.3 nmol.l-1 (1 ng.ml-1). As a corollary, the morphine/codeine ratio in the the concentration-time curves was less than 3% in all the patients. The systemic availability of codeine varied extensively between subjects (range 12-84%). This might partly explain differences in the dose of codeine required as an analgesic.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623909     DOI: 10.1007/bf00265933

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Analgesic potency of normorphine in patients with postoperative pain.

Authors:  L LASAGNA; T J DE KORNFELD
Journal:  J Pharmacol Exp Ther       Date:  1958-11       Impact factor: 4.030

2.  The effect of N-demethylation on certain pharmacologic actions of morphine, codeine, and meperidine in the mouse.

Authors:  J W MILLER; H H ANDERSON
Journal:  J Pharmacol Exp Ther       Date:  1954-10       Impact factor: 4.030

3.  Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.

Authors:  A Küpfer; B Schmid; R Preisig; G Pfaff
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

4.  Analgesic activity of morphine-6-glucuronide.

Authors:  R Osborne; S Joel; D Trew; M Slevin
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

5.  Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate.

Authors:  J C Shah; W D Mason
Journal:  J Clin Pharmacol       Date:  1990-08       Impact factor: 3.126

6.  Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.

Authors:  S H Sindrup; K Brøsen; P Bjerring; L Arendt-Nielsen; U Larsen; H R Angelo; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1990-12       Impact factor: 6.875

7.  Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.

Authors:  Z R Chen; A A Somogyi; G Reynolds; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

8.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

9.  Comparative disposition of codeine and pholcodine in man after single oral doses.

Authors:  J W Findlay; A S Fowle; R F Butz; E C Jones; B C Weatherley; R M Welch; J Posner
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

10.  Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.

Authors:  Q Y Yue; J Hasselström; J O Svensson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

View more
  6 in total

1.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

2.  Analgesic effect and plasma concentrations of codeine and morphine after two dose levels of codeine following oral surgery.

Authors:  H Quiding; G Lundqvist; L O Boréus; U Bondesson; J Ohrvik
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers.

Authors:  C H Wilder-Smith; E Hufschmid; W Thormann
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

4.  Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan.

Authors:  K Persson; S Sjöström; I Sigurdardottir; V Molnár; M Hammarlund-Udenaes; A Rane
Journal:  Br J Clin Pharmacol       Date:  1995-02       Impact factor: 4.335

5.  Recent advances in the use of opioids for cancer pain.

Authors:  Joanne Droney; Julia Riley
Journal:  J Pain Res       Date:  2009-09-23       Impact factor: 3.133

6.  A Novel Maintenance Therapeutic for Opioid Use Disorder.

Authors:  Beth Youngblood; Kevin Li; Donald R Gehlert; Julio C Medina; Neil Schwartz
Journal:  J Pharmacol Exp Ther       Date:  2021-05-19       Impact factor: 4.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.